» Articles » PMID: 35585518

Adverse Effects Following COVID-19 Vaccination in Iran

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2022 May 18
PMID 35585518
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vaccination is a key intervention to prevent COVID-19. Many vaccines are administered globally, yet there is not much evidence regarding their safety and adverse effects. Iran also faces this challenge, especially as data regarding the Sputnik V vaccine is sparse. Therefore, the aim of this study is to determine the adverse effects of the most commonly used vaccines in Iran.

Methods: Using a retrospective cohort study design, 6600 subjects aged 18 years or older who had received two doses of any of the three COVID-19 vaccines (Sinopharm, AstraZeneca, and Sputnik V) were selected using a random sampling method between March and August 2021. Subjects were asked about any adverse effects of the vaccines by trained interviewers via telephone interview. Vaccine-related adverse effects in individuals during the first 72 h and subsequently following both doses of the vaccines were determined. The demographic variables, type of administered vaccine, adverse effects, and history of the previous infection with COVID-19 were collected. Descriptive statistics (mean, standard deviation) and analytical statistics (Chi-squared and Wilcoxon tests) were performed at a 95% significance level using STATA software version 15 (STATA Corp, College Station, TX, USA).

Results: From 6600 participants, 4775 responded (response rate = 72.3%). Of the participants, 1460 (30.6%) received the AstraZeneca vaccine, 1564 (32.8%) received the Sinopharm vaccine and 1751 (36.7%) received the Sputnik V vaccine. 2653 participants (55.56%) reported adverse effects after the first dose and 1704 (35.7%) after the second dose. Sputnik V caused the most adverse effects with 1449 (82.7%) vaccine recipients reporting symptoms after the first or second dose, compared with 1030 (70.5%) for AstraZeneca and only 585 (37.4%) for the Sinopharm vaccine. The most common adverse effects after the first dose were fatigue (28.37%), chill/fever (26.86%), and skeletal pain (22.38%). These three adverse effects were the same for the second dose, although their prevalence was lower.

Conclusions: In this study, we demonstrate that the Sputnik V vaccine has the highest rate of adverse effects, followed by the AstraZeneca and Sinopharm vaccines. COVID-19 vaccines used in Iran are safe and there were no reports of serious adverse effects.

Citing Articles

Report on adverse events of COVID-19 vaccines in Iran: a comprehensive national prospective longitudinal analysis.

Jamaati H, Karimi S, Arshi S, Zahraei S, Panahi Y, Nouri F Front Immunol. 2025; 16:1504973.

PMID: 40028315 PMC: 11868111. DOI: 10.3389/fimmu.2025.1504973.


Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study.

Soltani S, Moradinazar M, Karamimatin B, Gouya M, Zahraei S, Moradi G BMC Public Health. 2025; 25(1):650.

PMID: 39962455 PMC: 11834735. DOI: 10.1186/s12889-025-21805-5.


Side Effects of COVID-19 Vaccines in Iraqi Kurdistan: A Population-Based Study.

Naqid I, Mosa A, Hito L, Jamil D, Shukur I, Abdulkareem D Cureus. 2024; 16(10):e71170.

PMID: 39525127 PMC: 11549252. DOI: 10.7759/cureus.71170.


Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.

Sharif N, Opu R, Saha T, Khan A, Aljohani A, Alsuwat M Sci Rep. 2024; 14(1):23794.

PMID: 39394252 PMC: 11470050. DOI: 10.1038/s41598-024-75833-z.


The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran.

Razimoghadam M, Daroudi R, Yaseri M J Glob Health. 2024; 14:05026.

PMID: 39325919 PMC: 11426934. DOI: 10.7189/jogh.14.05026.


References
1.
Tobaiqy M, Elkout H, MacLure K . Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines (Basel). 2021; 9(4). PMC: 8074142. DOI: 10.3390/vaccines9040393. View

2.
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021; 21(7):939-949. PMC: 8078878. DOI: 10.1016/S1473-3099(21)00224-3. View

3.
Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi S, Ovaise G . Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep. 2021; 11(1):21464. PMC: 8563977. DOI: 10.1038/s41598-021-00963-7. View

4.
Almufty H, Mohammed S, Abdullah A, Merza M . Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021; 15(5):102207. PMC: 8274281. DOI: 10.1016/j.dsx.2021.102207. View

5.
Raoofi A, Takian A, Akbari Sari A, Olyaeemanesh A, Haghighi H, Aarabi M . COVID-19 Pandemic and Comparative Health Policy Learning in Iran. Arch Iran Med. 2020; 23(4):220-234. DOI: 10.34172/aim.2020.02. View